New Frontiers and Treatment Paradigms for Thyroid Carcinoma  


Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

3.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in thyroid carcinoma.

Release Date

July 10, 2014

Expiration Date

July 10, 2016

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 3, 2014 through July 3, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 7 segments totaling 3.0 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.


Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Eisai, Inc.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. Complete Conference Management is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

(Program Co-Chairman)
Department Chair
Department of Endocrine Neoplasia and Hormonal Disorders
Naguib Samaan Distinguished Professor in Endocrinology
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Consultant: Amgen, Bayer, Eisai, Exelixis
Grant/Research Support: Genzyme, NCI

(Program Co-Chairman)
Associate Professor of Medicine
Harvard Medical School
Disease Center Leader; Head and Neck Oncology
Dana-Farber Cancer Institute
Boston, MA

Grant/Research Support: Boehringer Ingelheim (PI), BMS (PI)

Professor of Surgery,
E W Strong Chair in Head and Neck Oncology
Weil Medical College of Cornell University
Chief, Head and Neck Service
Memorial Sloan Kettering Cancer Center
New York, NY

Nothing to disclose

Assistant Professor
Harvard Medical School
Medical Director, Center for Head and Neck Cancers
Massachusetts General Hospital
Boston, MA

Consultant: Novartis, Eisai

Program Managers Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Characterize the epidemiology of thyroid carcinomas, and understand the origin of these cancers, their cure rates, and the unmet need for therapies against radioactive iodine refractory (or resistant) differentiated thyroid cancer (RAIR-DTC);
  • Interpret and apply the results—including efficacy, safety, side effect profiles, and PFS and OS outcomes—of late-breaking phase II and phase III clinical trials with MKIs, and better define the role of these agents in patients with RAIR-DTC.
  • Understand the efficacy of the standard of care for thyroid follicular cell cancer, which includes surgery and I-131;
  • Understand the emergence of new approaches to treat the significant percentage of patients who develop RAIR-DTC despite standard therapy, and who, therefore, require additional treatment to prolong survival or cure their disease;
  • Describe the role of tyrosine kinase inhibitors (TKIs) in iodine-refractory thyroid cancer and how, based on evidence from clinical trials, these agents can affect response rate and potentially prolong progression-free survival (PFS) and overall survival (OS) of thyroid cancer;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2014 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC




I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC



Key Program Topics Include:

anti-angiogenic tyrosine kinase inhibitor

lymph node
multikinase inhibitor


Radioactive iodine
Radioactive Iodine-Resistant Differentiated
radioiodide refractory
Thyroid Cancer

Thyroid carcinoma
TSH receptor